AELIS FARMA Email Format
Biotechnology ResearchNouvelle-aquitaine, France11-50 Employees
Aelis Farma is a clinical-stage biopharmaceutical company in the biotechnology research industry, based in Bordeaux, France, at 1 Rue Lafaurie de Monbadon, Nouvelle-aquitaine 33000. It develops treatments for brain diseases and is pursuing a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) to address brain pathologies while aiming to preserve normal behavior. Its lead drug candidates include AEF0117 for cannabis use disorder, in a phase 2b trial, and AEF0217 for cognitive deficits including Down syndrome, in early-phase studies with planned phase 1/2 development. The company operates with 11 to 50 employees and is based within the Inserm Magendie Neurocentre in Bordeaux. Since its founding in 2013, Aelis Farma has attracted investments from regional and research-focused partners, including the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, ACI, NACO, Aqui-invest, and IRDI Capital Investissement. More information is available on its website at https://aelisfarma.com.